Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Cirrhosis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 193 articles:
HTML format
Text format



Single Articles


    September 2017
  1. THABUT D, Pauwels A, Carbonell N, Remy AJ, et al
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32281.
    PubMed     Text format     Abstract available


  2. MOOKERJEE RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, et al
    Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    J Hepatol. 2017 Sep 8. pii: S0168-8278(17)32209.
    PubMed     Text format    


  3. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  4. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  5. GROSSI G, Loglio A, Facchetti F, Borghi M, et al
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32260.
    PubMed     Text format     Abstract available


    August 2017
  6. SHARMA SA, Kowgier M, Hansen BE, Pieter Brouwer W, et al
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.
    J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248.
    PubMed     Text format     Abstract available


  7. MAJUMDAR A, Bailey M, Kemp WM, Bellomo R, et al
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32198.
    PubMed     Text format     Abstract available


  8. THALHEIMER U, Giannelli V, Maimone S
    Non selective beta blockers in cirrhosis.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32194.
    PubMed     Text format    


  9. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Erratum to "Human liver regeneration in advanced cirrhosis is organized by the portal tree" [J Hepatol 66 (2017) 778-786].
    J Hepatol. 2017;67:430-436.
    PubMed     Text format    


    July 2017
  10. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Text format     Abstract available


  11. PIANO S, Tonon M, Vettore E, Stanco M, et al
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32151.
    PubMed     Text format     Abstract available


  12. ROBERTO C, Valeria R, Cristina N, Simona B, et al
    Gut-derived endotoxin stimulates factor viii secretion from endothelial cells. implications for hypercoagulability in cirrhosis.
    J Hepatol. 2017 Jul 14. pii: S0168-8278(17)32145.
    PubMed     Text format     Abstract available


  13. WEISS N, Colsch B, Fenaille F, Junot C, et al
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: do we really face two different entities?
    J Hepatol. 2017 Jul 5. pii: S0168-8278(17)32140.
    PubMed     Text format    


    June 2017
  14. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  15. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  16. ARTRU F, Louvet A, Ruiz I, Levesque E, et al
    Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32079.
    PubMed     Text format     Abstract available


  17. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32074.
    PubMed     Text format    


  18. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  19. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed     Text format    


  20. KALAMBOKIS GN, Baltayannis G, Christodoulou D, Christou L, et al
    Beta adrenergic blockade and advanced cirrhosis: does it really improve survival in patients with acute-on-chronic liver failure?
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32064.
    PubMed     Text format    


    May 2017
  21. SHIN WJ, Hwang GS
    Reply to: "Pressure volume curves in cirrhosis: more than meets the eye".
    J Hepatol. 2017 May 9. pii: S0168-8278(17)32010.
    PubMed     Text format    


  22. RIPOLL C, Yotti R, Banares R, Bermejo J, et al
    Pressure Volume Curves in Cirrhosis: more than meets the eye.
    J Hepatol. 2017 May 8. pii: S0168-8278(17)32006.
    PubMed     Text format    


    April 2017
  23. BRITO-AZEVEDO A
    Carvedilol and survival in cirrhosis with ascites: a cognitive bias?
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30219.
    PubMed     Text format    


  24. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  25. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


    February 2017
  26. SINHA R, Lockman KA, Mallawaarachchi N, Robertson M, et al
    Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30073.
    PubMed     Text format     Abstract available


  27. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


    January 2017
  28. BOURSIER J, de Ledinghen V, Leroy V, Anty R, et al
    A stepwise algorithm using a at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30007.
    PubMed     Text format     Abstract available


    December 2016
  29. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    


  30. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    


  31. WEISS E, Rautou PE, Fasseu M, Giabicani M, et al
    Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30741.
    PubMed     Text format     Abstract available


  32. ARROYO V, Moreau R
    Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis.
    J Hepatol. 2016 Dec 15. pii: S0168-8278(16)30577.
    PubMed     Text format    


  33. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  34. MONTAGNESE S, De Rui M, Angeli P, Amodio P, et al
    Neuropsychiatric Performance in Patients with Cirrhosis: Who is "Normal"?
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30698.
    PubMed     Text format     Abstract available


    November 2016
  35. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Human liver regeneration in advanced cirrhosis is organized by the portal tree.
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30690.
    PubMed     Text format     Abstract available


  36. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  37. REIBERGER T, Mandorfer M
    Beta adrenergic blockade and decompensated cirrhosis.
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30647.
    PubMed     Text format     Abstract available


    October 2016
  38. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    


  39. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  40. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    


    September 2016
  41. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  42. SHIN WJ, Song JG, Jun IG, Moon YJ, et al
    Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30536.
    PubMed     Text format     Abstract available


    August 2016
  43. BRITO-AZEVEDO A, Perez RM, Moraes Coelho HS, Fernandes ES, et al
    The Anti-inflammatory Role of Propranolol in Cirrhosis: Preventing the Inflammatory Exhaustion?
    J Hepatol. 2016 Aug 16. pii: S0168-8278(16)30432.
    PubMed     Text format    


    July 2016
  44. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  45. SOLA E, Kerbert JC, Verspaget HW, Moreira R, et al
    Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis.
    J Hepatol. 2016 Jul 12. pii: S0168-8278(16)30326.
    PubMed     Text format     Abstract available


  46. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  47. STEIN E, Cruz-Lemini M, Altamirano J, Ndugga N, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30307.
    PubMed     Text format     Abstract available


  48. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


  49. MAURICE J, Brodkin E, Arnold F, Navaratnam A, et al
    Validation of the Baveno Vi Criteria to Identify Low Risk Cirrhotic Patients not Requiring Endoscopic Surveillance for Varices.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30316.
    PubMed     Text format     Abstract available


    June 2016
  50. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  51. KOZBIAL K, Moser S, Schwarzer R, Laferl H, et al
    Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30271.
    PubMed     Text format    


  52. DAVULURI G, Krokowski D, Guan BJ, Kumar A, et al
    Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of L-leucine in cirrhosis.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30266.
    PubMed     Text format     Abstract available


  53. RATZIU V, Marchesini G
    When the journey from obesity to cirrhosis takes an early start.
    J Hepatol. 2016 Jun 14. pii: S0168-8278(16)30207.
    PubMed     Text format    


  54. SINCLAIR M, Grossmann M, Hoermann R, Angus PW, et al
    Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30269.
    PubMed     Text format     Abstract available


  55. KALAMBOKIS GN, Oikonomou A, Christou L, Kolaitis NI, et al
    von Willebrand factor and procoagulant imbalance independently predict outcome in patients with cirrhosis and thrombocytopenia.
    J Hepatol. 2016 Jun 10. pii: S0168-8278(16)30262.
    PubMed     Text format     Abstract available


    May 2016
  56. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Corrigendum to "Management of the critically ill patients with cirrhosis: A multidisciplinary perspective".
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30185.
    PubMed     Text format    


  57. FRANCOZ C, Nadim MK, Durand F
    Kidney Biomarkers in Cirrhosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30211.
    PubMed     Text format     Abstract available


  58. OLESEN SS, Gram M, Jackson CD, Halliday E, et al
    Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy.
    J Hepatol. 2016 May 13. pii: S0168-8278(16)30189.
    PubMed     Text format     Abstract available


  59. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


    April 2016
  60. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  61. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  62. MARI M, Tutusaus A, Garcia de Frutos P, Morales A, et al
    Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis.
    J Hepatol. 2016;64:983-4.
    PubMed     Text format    


  63. PETTA S, Marra F
    Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'.
    J Hepatol. 2016;64:984-5.
    PubMed     Text format    


  64. DUBUQUOY L
    Lipocalin 2 highlights the complex role of neutrophils in alcoholic liver disease.
    J Hepatol. 2016;64:770-2.
    PubMed     Text format    


  65. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Text format     Abstract available


    March 2016
  66. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  67. ARIZA X, Graupera I, Coll M, Sola E, et al
    Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.
    J Hepatol. 2016 Mar 14. pii: S0168-8278(16)30029.
    PubMed     Text format     Abstract available


  68. CURRY MP
    DAA for decompensated cirrhosis. Efficacy and safety are now established.
    J Hepatol. 2016 Mar 3. pii: S0168-8278(16)30007.
    PubMed     Text format    


  69. PETTA S, Valenti L, Marra F, Grimaudo S, et al
    MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:682-90.
    PubMed     Text format     Abstract available


  70. MOOKERJEE RP, Pavesi M, Thomsen KL, Mehta G, et al
    Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
    J Hepatol. 2016;64:574-82.
    PubMed     Text format     Abstract available


    February 2016
  71. BUCSICS T, Schwabl P, Mandorfer M, Peck-Radosavljevic M, et al
    Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP).
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00155.
    PubMed     Text format    


  72. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Reply to "Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis".
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00121.
    PubMed     Text format    


  73. LOUVET A
    Restoration of bactericidal activity of neutrophils by myeloperoxidase release: a new perspective for preventing infection in alcoholic cirrhosis.
    J Hepatol. 2016 Feb 13. pii: S0168-8278(16)00125.
    PubMed     Text format    


  74. ESLAM M, Hashem AM, Romero-Gomez M, Berg T, et al
    FibroGENE: A gene-based model for staging liver fibrosis.
    J Hepatol. 2016;64:390-8.
    PubMed     Text format     Abstract available


    January 2016
  75. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  76. TREBICKA J, von Heydebrand M, Lehmann J, Tofteng F, et al
    Assessment of beta-blocker response by expression of beta-Arrestin2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.
    J Hepatol. 2016 Jan 28. pii: S0168-8278(16)00057.
    PubMed     Text format     Abstract available


  77. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  78. LUA I, Li Y, Zagory JA, Wang KS, et al
    Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers.
    J Hepatol. 2016 Jan 19. pii: S0168-8278(16)00015.
    PubMed     Text format     Abstract available


  79. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  80. MCPHAIL MJ, Shawcross DL, Lewis MR, Coltart I, et al
    Multivariate metabotyping of plasma accurately predicts survival in patients with decompensated cirrhosis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00006.
    PubMed     Text format     Abstract available


  81. FIORE M, Leone S
    Use of anti-fungals in critically ill cirrhotic patients with spontaneous peritonitis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00013.
    PubMed     Text format    


  82. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  83. CASTERA L
    Non-invasive tests for liver fibrosis progression and regression.
    J Hepatol. 2016;64:232-3.
    PubMed     Text format    


  84. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


  85. KARSDAL MA, Genovese F, Madsen EA, Manon-Jensen T, et al
    Collagen and tissue turnover as a function of age: Implications for fibrosis.
    J Hepatol. 2016;64:103-9.
    PubMed     Text format     Abstract available


  86. JIANG M, Klein M, Zanger UM, Mohammad MK, et al
    Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease.
    J Hepatol. 2016;64:44-52.
    PubMed     Text format     Abstract available


    December 2015
  87. GARCIA-TSAO G
    Beta-Blockers in Cirrhosis: The Window Re-Opens.
    J Hepatol. 2015 Dec 24. pii: S0168-8278(15)00814.
    PubMed     Text format    


  88. UBEDA M, Lario M, Munoz L, Borrero MJ, et al
    Obeticholic acid reduces bacterial translocation, restores intestinal barrier and inhibits inflammation in cirrhotic rats.
    J Hepatol. 2015 Dec 23. pii: S0168-8278(15)00812.
    PubMed     Text format     Abstract available


  89. BOUSSIF A, Rolas L, Weiss E, Bouriche H, et al
    Impaired AKT/MAP-Kinase signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis.
    J Hepatol. 2015 Dec 21. pii: S0168-8278(15)00806.
    PubMed     Text format     Abstract available


  90. CERINI F, Vilaseca M, Lafoz E, Garcia-Irigoyen O, et al
    Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    J Hepatol. 2015 Dec 11. pii: S0168-8278(15)00804.
    PubMed     Text format     Abstract available


    November 2015
  91. KOOT BG, Alders M, Verheij J, Beuers UH, et al
    A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00785.
    PubMed     Text format     Abstract available


  92. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  93. GRONBAEK H, Rodgaard-Hansen S, Aagaard NK, Arroyo V, et al
    The soluble macrophage activation markers sCD163 and Mannose Receptor (sMR) predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    J Hepatol. 2015 Nov 27. pii: S0168-8278(15)00779.
    PubMed     Text format     Abstract available


  94. PAGE A, Paoli P, Moran Salvador E, White S, et al
    Hepatic Stellate Cell Transdifferentiation Involves Genome-Wide Remodeling of the DNA Methylation Landscape.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00782.
    PubMed     Text format     Abstract available


  95. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  96. EGUCHI A, Jeu XM, Johnson CD, Nektaria A, et al
    Liver Bid-suppression for treatment of fibrosis associated with nonalcoholic steatohepatitis.
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00732.
    PubMed     Text format     Abstract available


    October 2015
  97. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00718.
    PubMed     Text format    


  98. ORO D, Yudina T, Fernandez-Varo G, Casals E, et al
    Cerium oxide nanoparticles reduce steatosis, portal hypertension and display antiinflammatory properties in rats with liver fibrosis.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00719.
    PubMed     Text format     Abstract available


  99. FELD JJ, Moreno C, Trinh R, Tam E, et al
    Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks.
    J Hepatol. 2015 Oct 14. pii: S0168-8278(15)00676.
    PubMed     Text format     Abstract available


  100. CHUNG SI, Moon H, Ju HL, Cho KJ, et al
    Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model.
    J Hepatol. 2015 Oct 12. pii: S0168-8278(15)00678.
    PubMed     Text format     Abstract available


    September 2015
  101. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    J Hepatol. 2015 Sep 10. pii: S0168-8278(15)00459.
    PubMed     Text format    


  102. GALBOIS A, Maury E, Guidet B, Ait-Oufella H, et al
    Reply to: "Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?".
    J Hepatol. 2015;63:772-3.
    PubMed     Text format    


  103. CASSINOTTO C, de Ledinghen V
    Reply to: "New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?".
    J Hepatol. 2015;63:767.
    PubMed     Text format    


  104. LANTHIER N, Starkel P, Horsmans Y
    New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?
    J Hepatol. 2015;63:765-6.
    PubMed     Text format    


    August 2015
  105. MORATALLA A, Caparros E, Juanola O, Portune K, et al
    Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00592.
    PubMed     Text format     Abstract available


  106. BUREAU C, Laurent J, Robic MA, Christol C, et al
    Central obesity is associated with non-cirrhotic portal-vein thrombosis.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00596.
    PubMed     Text format     Abstract available


  107. LEI XF, Fu W, Kim-Kaneyama JR, Omoto T, et al
    Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00598.
    PubMed     Text format     Abstract available


  108. KAMATH PS, Poterucha JJ, Ludwig J
    Primary Biliary Cirrhosis by Another Name is Still PBC.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00555.
    PubMed     Text format    


  109. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  110. BOSCH A, Dumortier J, Maucort-Boulch D, Scoazec JY, et al
    Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
    J Hepatol. 2015 Aug 14. pii: S0168-8278(15)00545.
    PubMed     Text format     Abstract available


    July 2015
  111. TODD STRAVITZ R, Reuben A, Mizrahi M, Lalazar G, et al
    Use of the Methacetin Breath Test to Classify the Risk of Cirrhotic Complications and Mortality in Patients Evaluated/Listed for Liver Transplantation.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00512.
    PubMed     Text format     Abstract available


  112. ZHENG Z, Zhang X, Wang J, Dandeka A, et al
    Exposure to Fine Airborne Particulate Matters Induces Hepatic Fibrosis in Murine Models.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00511.
    PubMed     Text format     Abstract available


  113. EL-SHAMY A, Eng FJ, Doyle EH, Klepper AL, et al
    A Cell Culture System for Distinguishing Hepatitis C Viruses with and without Liver Cancer-related Mutations in the Viral Core Gene.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00515.
    PubMed     Text format     Abstract available


  114. BERZIGOTTI A, Boyer TD, Castera L, de Franchis R, et al
    Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus".
    J Hepatol. 2015 Jul 23. pii: S0168-8278(15)00475.
    PubMed     Text format    


  115. JEPSEN P, Watson H, Andersen PK, Vilstrup H, et al
    Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.
    J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00470.
    PubMed     Text format     Abstract available


  116. PERAZZO H, Fernandes FF, Castro Filho EC, Perez RM, et al
    Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus.
    J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00468.
    PubMed     Text format    


  117. YANG YH, Chen WC, Tsan YT, Chen MJ, et al
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2015 Jul 18. pii: S0168-8278(15)00469.
    PubMed     Text format     Abstract available


  118. BERNARDI M, Moreau R, Angeli P, Schnabl B, et al
    Mechanisms of Decompensation and Organ Failure in Cirrhosis: From Peripheral arterial Vasodilation to Systemic Inflammation Hypothesis.
    J Hepatol. 2015 Jul 17. pii: S0168-8278(15)00466.
    PubMed     Text format     Abstract available


    June 2015
  119. FERENCI P, Kozbial K, Mandorfer M, Hofer H, et al
    HCV targeting of patients with cirrhosis.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00393.
    PubMed     Text format     Abstract available


  120. LAMPERTICO P, Invernizzi F, Vigano M, Loglio A, et al
    The long-term benefits of nucleos(t)ide analogs on esophageal varices in compensated HBV cirrhotics with no or small esophageal varices: A 12-year prospective cohort study.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00397.
    PubMed     Text format     Abstract available


  121. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Fungal Infections in patients with cirrhosis.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00396.
    PubMed     Text format    


  122. COUDROY R, Jamet A, Thille AW
    Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?
    J Hepatol. 2015 Jun 5. pii: S0168-8278(15)00383.
    PubMed     Text format    


    May 2015
  123. YADA A, Iimuro Y, Uyama N, Uda Y, et al
    Splenectomy attenuates murine liver fibrosis with hypersplenism stimulating hepatic accumulation of Ly-6C macrophages.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00337.
    PubMed     Text format     Abstract available


  124. FARRAR CT, DePeralta DK, Day H, Rietz TA, et al
    3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00335.
    PubMed     Text format     Abstract available


  125. DA SILVA MIOZZO SA, Tovo CV, John JA, de Mattos AA, et al
    Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: an undesirable association?
    J Hepatol. 2015 May 23. pii: S0168-8278(15)00334.
    PubMed     Text format    


  126. THEVENOT T, Monnet E, Di Martino V
    Reply to "Albumin infusion in cirrhotic patients with non-SBP infections: end of the story?"
    J Hepatol. 2015 May 18. pii: S0168-8278(15)00330.
    PubMed     Text format    


  127. MERLI M, Lucidi C, Lattanzi B, Riggio O, et al
    Albumin infusion in cirrhotic patients with infections other than Spontaneous Bacterial Peritonitis: end of the story?
    J Hepatol. 2015 May 16. pii: S0168-8278(15)00329.
    PubMed     Text format    


  128. MEHTA G, Dusheiko G
    Hepatitis C treatment and quality of life - you can't always get what you want, but you might get what you need.
    J Hepatol. 2015 May 13. pii: S0168-8278(15)00326.
    PubMed     Text format    


  129. ADAMS LA, Ratziu V
    Non-alcoholic fatty liver - perhaps not so benign.
    J Hepatol. 2015;62:1002-4.
    PubMed     Text format    


    April 2015
  130. MANNAERTS I, Leite SB, Verhulst S, Claerhout S, et al
    The Hippo pathway effector YAP controls mouse hepatic stellate cell activation.
    J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00294.
    PubMed     Text format     Abstract available


  131. BARCENA C, Stefanovic M, Tutusaus A, Joannas L, et al
    Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.
    J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00296.
    PubMed     Text format     Abstract available


  132. BOURSIER J, de Ledinghen V, Poynard T, Guechot J, et al
    An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.
    J Hepatol. 2015;62:807-15.
    PubMed     Text format     Abstract available


  133. TRAUTWEIN C, Friedman SL, Schuppan D, Pinzani M, et al
    Hepatic fibrosis: Concept to treatment.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


    March 2015
  134. LAURIDSEN MM, Bajaj JS
    Hepatic Encephalopathy Treatment and Driving: A Continental Divide.
    J Hepatol. 2015 Mar 18. pii: S0168-8278(15)00195.
    PubMed     Text format    


  135. YOUNOSSI ZM, Stepanova M, Afdhal N, Kowdley KV, et al
    Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    J Hepatol. 2015 Mar 17. pii: S0168-8278(15)00192.
    PubMed     Text format     Abstract available


  136. WONG F, O'Leary JG, Reddy KR, Kamath PS, et al
    A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be.
    J Hepatol. 2015;62:741-3.
    PubMed     Text format    


  137. FAGUNDES C, Barreto R, Rodriguez E, Graupera I, et al
    Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be".
    J Hepatol. 2015;62:743-4.
    PubMed     Text format    


  138. PIANO S, Tonon M, Cavallin M, Morando F, et al
    Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be".
    J Hepatol. 2015;62:744-6.
    PubMed     Text format    


  139. MEIER RP, Mahou R, Morel P, Meyer J, et al
    Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice.
    J Hepatol. 2015;62:634-41.
    PubMed     Text format     Abstract available


  140. PAWLAK M, Lefebvre P, Staels B
    Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:720-33.
    PubMed     Text format     Abstract available


  141. ALTROCK E, Sens C, Wuerfel C, Vasel M, et al
    Inhibition of fibronectin deposition improves experimental liver fibrosis.
    J Hepatol. 2015;62:625-33.
    PubMed     Text format     Abstract available


    February 2015
  142. SIMON TG, King LY, Chung RT
    Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
    J Hepatol. 2015 Feb 26. pii: S0168-8278(15)00138.
    PubMed     Text format    


  143. BITTO N, Salerno F, Tripodi A, Mura V, et al
    Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
    J Hepatol. 2015 Feb 25. pii: S0168-8278(15)00137.
    PubMed     Text format    


  144. KOCABAYOGLU P, Lade A, Lee YA, Dragomir AC, et al
    beta-PDGF Receptor Expressed by Hepatic Stellate Cells Regulates Fibrosis in Murine Liver Injury, but Not Carcinogenesis.
    J Hepatol. 2015 Feb 9. pii: S0168-8278(15)00073.
    PubMed     Text format     Abstract available


    January 2015
  145. NEGRO F
    Are statins a remedy for all seasons?
    J Hepatol. 2015;62:8-10.
    PubMed     Text format    


  146. FORNER A, Vilana R, Bianchi L, Rodriguez-Lope C, et al
    Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.
    J Hepatol. 2015;62:150-5.
    PubMed     Text format     Abstract available


  147. CUBERO FJ, Zhao G, Nevzorova YA, Hatting M, et al
    Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury.
    J Hepatol. 2015;62:140-9.
    PubMed     Text format     Abstract available


    December 2014
  148. MORGAN TR
    Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding.
    J Hepatol. 2014 Dec 24. pii: S0168-8278(14)00942.
    PubMed     Text format    


  149. KLUGER MD, Salceda JA, Laurent A, Tayar C, et al
    Liver Resection For Hepatocellular Carcinoma in 313 Western Patients: Tumor Biology and Underlying Liver Rather than Tumor Size Drive Prognosis.
    J Hepatol. 2014 Dec 18. pii: S0168-8278(14)00939.
    PubMed     Text format     Abstract available


  150. MORRISON MC, Liang W, Mulder P, Verschuren L, et al
    Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE *3Leiden mice.
    J Hepatol. 2014 Dec 13. pii: S0168-8278(14)00929.
    PubMed     Text format     Abstract available


    November 2014
  151. MCPHERSON S, Hardy T, Henderson E, Burt AD, et al
    Evidence of NAFLD Progression from Steatosis to Fibrosing-Steatohepatitis Using Paired Biopsies: Implications for Prognosis & Clinical Management.
    J Hepatol. 2014 Nov 29. pii: S0168-8278(14)00883.
    PubMed     Text format     Abstract available


  152. KIM GA, Lee HC, Kim MJ, Ha Y, et al
    Incidence of Hepatocellular Carcinoma after HBsAg Seroclearance in Chronic Hepatitis B Patients: a Need for Surveillance.
    J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00880.
    PubMed     Text format     Abstract available


  153. LUNOVA M, Nahon P, Trautwein C, Strnad P, et al
    Hepcidin in chronic liver disease and hepatocellular carcinoma: the plot thickens.
    J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00851.
    PubMed     Text format    


  154. SOMBETZKI M, Fuchs CD, Fickert P, Oesterreicher C, et al
    24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
    J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00865.
    PubMed     Text format     Abstract available


  155. RUDLER M, Mouri S, Charlotte F, Lebray P, et al
    Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding.
    J Hepatol. 2014 Nov 11. pii: S0168-8278(14)00818.
    PubMed     Text format     Abstract available


  156. WESTBROOK RH, Dusheiko G
    Natural history of hepatitis C.
    J Hepatol. 2014;61.
    PubMed     Text format     Abstract available


    October 2014
  157. HUANG CF, Dai CY, Yeh ML, Huang CI, et al
    Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection.
    J Hepatol. 2014 Oct 20. pii: S0168-8278(14)00740.
    PubMed     Text format     Abstract available


  158. GUO R, Xu X, Babcock SA, Zhang Y, et al
    Aldehyde Dehydrogenase-2 (ALDH2) Ameliorates Chronic Alcohol Ingestion-Induced Hepatic Steatosis and Inflammation: Role of Autophagy.
    J Hepatol. 2014 Oct 20. pii: S0168-8278(14)00738.
    PubMed     Text format     Abstract available


  159. SECKLEHNER J, Richardson CA
    The reporting of animal welfare details in liver research: A review of studies describing bile duct ligation in mice (2011-2013).
    J Hepatol. 2014 Oct 1. pii: S0168-8278(14)00720.
    PubMed     Text format    


    September 2014
  160. SHOUVAL D, Friedman SL
    Focusing on the Past, Present and Future of Hepatology.
    J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00627.
    PubMed     Text format    


    August 2014
  161. SIMON TG, King LY, Zheng H, Chung RT, et al
    Statin Use is Associated with a Reduced Risk of Fibrosis Progression in Chronic Hepatitis C.
    J Hepatol. 2014 Aug 15. pii: S0168-8278(14)00552.
    PubMed     Text format     Abstract available


  162. CHEN L, Li J, Zhang J, Dai C, et al
    S100A4 promotes liver fibrosis via activation of hepatic stellate cells.
    J Hepatol. 2014 Aug 8. pii: S0168-8278(14)00541.
    PubMed     Text format     Abstract available


  163. TIAN W, Hao C, Fan Z, Weng X, et al
    Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells.
    J Hepatol. 2014 Aug 7. pii: S0168-8278(14)00533.
    PubMed     Text format     Abstract available


    July 2014
  164. POYNARD T, Vergniol J, Ngo Y, Foucher J, et al
    Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest) and elastography (FibroScan).
    J Hepatol. 2014 Jul 9. pii: S0168-8278(14)00457.
    PubMed     Text format     Abstract available


  165. ZHANG L, Schuppan D
    Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype.
    J Hepatol. 2014;61:166-8.
    PubMed     Text format    


  166. TRIPODI A, Fracanzani AL, Primignani M, Chantarangkul V, et al
    Procoagulant imbalance in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2014;61:148-54.
    PubMed     Text format     Abstract available


  167. HUANG Y, de Boer WB, Adams LA, MacQuillan G, et al
    Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome.
    J Hepatol. 2014;61:22-7.
    PubMed     Text format     Abstract available


  168. CHIAVAROLI L, Ha V, Kendall CW, Sievenpiper JL, et al
    Is industrial fructose just a marker of an unhealthy dietary pattern?
    J Hepatol. 2014;61:172-3.
    PubMed     Text format    


  169. PETTA S, Marchesini G, Craxi A
    Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?".
    J Hepatol. 2014;61:173-5.
    PubMed     Text format    


    June 2014
  170. NISCHALKE HD, Lutz P, Kramer B, Sohne J, et al
    A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease.
    J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00401.
    PubMed     Text format     Abstract available


  171. COLOMBO M, Strasser SI, Moreno C, Ferreira PA, et al
    Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program.
    J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400.
    PubMed     Text format     Abstract available


    May 2014
  172. PINYOL R, Tovar V, Llovet JM
    TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma.
    J Hepatol. 2014 May 22. pii: S0168-8278(14)00375.
    PubMed     Text format    


  173. KROY DC, Schumacher F, Ramadori P, Hatting M, et al
    Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic-steatohepatitis in mice.
    J Hepatol. 2014 May 15. pii: S0168-8278(14)00360.
    PubMed     Text format     Abstract available


  174. HARRIS RJ, Thomas B, Griffiths J, Costella A, et al
    Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
    J Hepatol. 2014 May 10. pii: S0168-8278(14)00318.
    PubMed     Text format     Abstract available


  175. NI HM, Woolbright BL, Williams J, Copple B, et al
    Nrf2 Promotes the Development of Fibrosis and Tumorigenesis in Mice with Defective Hepatic Autophagy.
    J Hepatol. 2014 May 7. pii: S0168-8278(14)00306.
    PubMed     Text format     Abstract available


  176. MACALUSO FS, Maida M, Camma C, Cabibbo G, et al
    Steatosis Affects the Performance of Liver Stiffness Measurement for Fibrosis Assessment in Patients with Genotype 1 Chronic Hepatitis C.
    J Hepatol. 2014 May 7. pii: S0168-8278(14)00308.
    PubMed     Text format     Abstract available


  177. FRIEDMAN SL
    Replacing a crystal ball with a calculator in predicting liver disease outcomes.
    J Hepatol. 2014;60:905-6.
    PubMed     Text format    


  178. MCPHERSON S, Henderson E, Burt AD, Day CP, et al
    Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2014;60:1055-62.
    PubMed     Text format     Abstract available


  179. TACKE F, Zimmermann HW
    Macrophage heterogeneity in liver injury and fibrosis.
    J Hepatol. 2014;60:1090-6.
    PubMed     Text format     Abstract available


  180. ASRANI SK, Talwalkar JA, Kamath PS, Shah VH, et al
    Role of magnetic resonance elastography in compensated and decompensated liver disease.
    J Hepatol. 2014;60:934-9.
    PubMed     Text format     Abstract available


    April 2014
  181. MAAN R, van der Meer AJ, Hansen BE, Feld JJ, et al
    Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
    J Hepatol. 2014 Apr 26. pii: S0168-8278(14)00284.
    PubMed     Text format     Abstract available


  182. HEZODE C, Fontaine H, Barthe Y, Carrat F, et al
    Reply to: "From the CUPIC study: great times are not coming(?)".
    J Hepatol. 2014;60:900-1.
    PubMed     Text format    


  183. SCHMIDT-MARTIN D, Houlihan D, McCormick A
    From the CUPIC study: great times are not coming(?).
    J Hepatol. 2014;60:899-900.
    PubMed     Text format    


  184. SHAH HA, Azam Z, Rauf J, Abid S, et al
    Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.
    J Hepatol. 2014;60:757-64.
    PubMed     Text format     Abstract available


  185. MARINO Z, Mensa L, Crespo G, Miquel R, et al
    Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation.
    J Hepatol. 2014 Apr 1. pii: S0168-8278(14)00210.
    PubMed     Text format     Abstract available


    March 2014
  186. TOMITA K, Teratani T, Suzuki T, Shimizu M, et al
    Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells.
    J Hepatol. 2014 Mar 18. pii: S0168-8278(14)00164.
    PubMed     Text format     Abstract available


  187. DEUFFIC-BURBAN S, Schwarzinger M, Obach D, Mallet V, et al
    Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188).
    J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00155.
    PubMed     Text format     Abstract available


  188. LEROY V, Sturm N, Faure P, Trocme C, et al
    Prospective evaluation of Fibrotest, Fibrometer and Hepascore for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C.
    J Hepatol. 2014 Mar 11. pii: S0168-8278(14)00137.
    PubMed     Text format     Abstract available


    February 2014
  189. XU S, Wang Y, Tai DC, Wang S, et al
    qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients.
    J Hepatol. 2014 Feb 25. pii: S0168-8278(14)00121.
    PubMed     Text format     Abstract available


    January 2014
  190. MANINI MA, Sangiovanni A, Fornari F, Piscaglia F, et al
    Clinical and Economical Impact of 2010 AASLD Guidelines for the Diagnosis of Hepatocellular Carcinoma.
    J Hepatol. 2014 Jan 21. pii: S0168-8278(14)00049.
    PubMed     Text format     Abstract available


    December 2013
  191. FAGIUOLI S, Colli A, Bruno R, Craxi A, et al
    Management of infections pre- and post-liver transplantation: Report of a AISF Consensus Conference.
    J Hepatol. 2013 Dec 30. pii: S0168-8278(13)00890.
    PubMed     Text format     Abstract available


    November 2013
  192. POYNARD T, Vergniol J, Ngo Y, Foucher J, et al
    Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest) and transient elastography (FibroScan).
    J Hepatol. 2013 Nov 26. pii: S0168-8278(13)00817.
    PubMed     Text format     Abstract available


  193. SHOEB D, Dearden J, Weatherall A, Bargery C, et al
    Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    J Hepatol. 2013 Nov 26. pii: S0168-8278(13)00812.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: